What are the side effects of oral medroxyprogesterone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Side Effects of Oral Medroxyprogesterone Acetate

Oral medroxyprogesterone acetate (MPA) carries significant cardiovascular, metabolic, and thrombotic risks that must be weighed against its benefits, with the FDA labeling and recent guidelines consistently documenting adverse effects on lipid profiles, blood pressure, carbohydrate metabolism, and increased thromboembolism risk. 1

Cardiovascular and Metabolic Effects

MPA negatively impacts cardiovascular risk through multiple mechanisms:

  • Adverse lipid profile changes: MPA worsens lipid profiles compared to alternative progestins, particularly when combined with estrogen, attenuating the beneficial HDL-raising effects of estrogen therapy 2
  • Vasomotor dysfunction: MPA adversely affects vasomotion, potentially increasing cardiovascular risk 2
  • Carbohydrate metabolism impairment: MPA negatively impacts carbohydrate metabolism and can reduce glucose tolerance 2, 1
  • Blood pressure effects: When combined with ethinyl estradiol, MPA may worsen blood pressure, renal function, and activate the renin-angiotensin system 2

Thrombotic and Cerebrovascular Risks

The thrombotic risk profile of MPA is substantial and clinically significant:

  • Venous thromboembolism: Injectable depot MPA and combined hormonal contraceptives containing MPA increase thrombosis risk and should be avoided in women with chronic coronary disease or previous stroke 2
  • Stroke risk: When combined with estrogen, MPA increases stroke risk (relative risk 2.02 for venous thromboembolism) 2
  • Deep venous thrombosis and pulmonary embolism: Both are documented adverse events with MPA use 1

Common Side Effects

The FDA label documents the following common adverse reactions with oral MPA alone: 1

Gynecologic Effects

  • Abnormal uterine bleeding (irregular, increased, or decreased menstrual flow)
  • Breakthrough bleeding and spotting
  • Amenorrhea (absence of menstrual periods)
  • Changes in cervical secretions
  • Breast tenderness, mastodynia, or galactorrhea

Neuropsychiatric Effects

  • Headaches
  • Mental depression
  • Nervousness and dizziness
  • Insomnia, somnolence, or fatigue
  • Premenstrual syndrome-like symptoms

Metabolic and Physical Effects

  • Weight changes (increase or decrease)
  • Fluid retention and edema
  • Bloating and abdominal discomfort
  • Nausea

Dermatologic Effects

  • Acne
  • Alopecia (hair loss) or hirsutism (hair growth)
  • Urticaria, pruritus, and rash

Serious Adverse Events

When combined with estrogen, additional serious risks emerge: 1

  • Breast cancer: Small increase in invasive breast cancer incidence and breast cancer deaths 2
  • Endometrial effects: While MPA protects against endometrial hyperplasia when combined with estrogen, unopposed use increases endometrial cancer risk 2, 1
  • Gallbladder disease: Increased incidence documented 2, 1
  • Dementia: Increased risk when combined with estrogen in postmenopausal women 2
  • Urinary incontinence: Moderate harm documented 2

Emerging Safety Signals

Recent pharmacovigilance data from 2024 identified previously unreported adverse events: 3

  • Unintended pregnancy (despite contraceptive use)
  • Bone pain and osteonecrosis
  • Gait disturbance
  • Dental caries
  • Decreased blood pressure (paradoxically, in some patients)

Contraindications

MPA is absolutely contraindicated in: 1

  • Pregnancy (risk of minor birth defects in first trimester)
  • Current or history of breast cancer
  • Undiagnosed abnormal vaginal bleeding
  • Active or history of blood clots, stroke, or heart attack
  • Liver disease
  • Known hypersensitivity to MPA

Clinical Context and Alternatives

Despite these risks, MPA remains widely used because it is the only progestin with proven full effectiveness in inducing secretory endometrium when combined with estrogen. 2 However, the European Society for Human Reproduction and Embryology (ESHRE) now recommends natural micronized progesterone as an alternative due to its superior safety profile, particularly regarding cardiovascular and thrombotic risks 2

Monitoring Recommendations

Patients on MPA require: 1

  • Regular evaluation every 3-6 months to assess continued need
  • Annual pelvic exam, breast exam, and mammogram
  • More frequent breast surveillance if family history of breast cancer or previous abnormal findings
  • Immediate evaluation for warning signs: new breast lumps, unusual vaginal bleeding, vision changes, severe headaches, chest or leg pain, or signs of thromboembolism

References

2
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What dose of medroxyprogesterone acetate (Provera) should be given to induce menstruation?
What is the appropriate dosing regimen of Provera (medroxyprogesterone acetate) for menstrual suppression?
What are the contraindications and recommended dosing regimen of medroxyprogesterone acetate (Provera) for delaying menstruation?
What is the likely cause and recommended management for three months of breakthrough bleeding after a Depo‑Provera (medroxyprogesterone acetate) injection?
What is the half‑life of medroxyprogesterone acetate (including oral tablets, intramuscular depot injection, and subcutaneous depot injection)?
Can venlafaxine be taken twice daily?
What is the taper protocol for switching from aripiprazole (Abilify) 10 mg daily to iloperidone (Fanapt)?
Can nebivolol be used to treat anxiety in an adult patient, particularly when they also have hypertension or tachycardia?
Can fluoxetine (Prozac) and bupropion (Wellbutrin) be used together in adult patients?
Should I decrease the continuous milrinone infusion from 0.375 µg/kg/min to 0.25 µg/kg/min in a patient with a cardiac index of 3.1 L/min/m², mixed venous oxygen saturation of 61 %, mixed venous PCO₂ of 47 mm Hg, pH 7.34, mixed venous PO₂ of 33 mm Hg, and total CO₂ of 27 mm Hg?
How should a 50‑year‑old patient with severe hyponatraemia (serum sodium 121 mmol/L) and hyperkalaemia (serum potassium 5.5 mmol/L) presenting with a urinary tract infection and obstructive ureteric calculi be managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question